Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating a drug called ribociclib (LEE011) given in combination with
everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed
or refractory ALL.
The names of the drugs involved in this study are:
- ribociclib
- everolimus
- dexamethasone